Hematopoietic Stem Cell Transplantation Market Snapshot (2023 to 2033)
The global hematopoietic stem cell transplantation market garnered a market value of US$ 7 Billion in 2023 and is expected to accumulate a market value of US$ 15 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Because of the rising frequency of leukemia and lymphoma, the worldwide hematopoietic stem cell transplantation industry is predicted to rise significantly over the forecast period.
According to the Centers for Disease Control and Prevention (CDC), about 45,360 persons were diagnosed with leukemia in the United States in 2013, resulting in 23,549 deaths (13,625 men and 9,924 women). In accordance with the same source, men are more likely than women to have the illness. Leukemia contributes to approximately 3% of novel cancer cases.
Data Points
Key Statistics
Expected Market Value (2023)
US$ 7 Billion
Anticipated Forecast Value (2033)
US$ 15 Billion
Projected Growth Rate (2023 to 2033)
8% CAGR
Hematopoietic stem cell transplantation is a process in which multipotent hematopoietic stem cells are transferred into the patient from peripheral blood cells, bone marrow, or umbilical cord blood.
Lymphoma (Hodgkin and non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis are all widely treated by hematopoietic stem cell transplantation. It has two transplantation sources: autologous (using stem cells from the patient's own body) and allogeneic (using stem cells from a donor's body).
According to the World Health Organization (WHO), approximately 50,000 hematopoietic stem cell transplantation surgeries are carried out globally each year, with this figure anticipated to rise in the coming years. During the projected period, factors such as the increasing frequency of hematopoietic stem cell transplants are likely to drive market expansion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Hematopoietic Stem Cell Transplantation Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for hematopoietic stem cell transplantation is projected to increase at a CAGR of 8% during the forecast period between 2023 to 2032, reaching a total of US$ 15 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6%.
The worldwide hematopoietic stem cell transplantation market is going to expand rapidly due to an increase in the frequency of hematological illnesses, an increase in transplant success rates, and growth in the world's aging population. According to a Scientific America study report, global transplantation rates have grown from 50,000 HSC transplants per year in 2012 to 75,000 HSC transplants per year in 2015. However, high transplantation costs and a shortage of financing for organizations such as the Worldwide Network for Blood and Marrow Transplantation (WBMT) are projected to limit the worldwide hematopoietic stem cell transplantation industry over the projection period.
Which are Some Prominent Drivers of Hematopoietic Stem Cell Transplantation Market?
The rising Frequency of Leukaemia and Lymphoma is Propelling the Worldwide Hematopoietic Stem Cell Transplantation Market Forward
During the projected period, the rising frequency of leukemia and lymphoma is likely to boost the hematopoietic stem cell transplantation market.
According to the Leukemia and Lymphoma Society's 2019 report, an estimated 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma, and roughly 1,399,180 people were living with leukemia, lymphoma, or myeloma. The rising incidence rate is predicted to fuel demand for hematopoietic stem cell transplantation, driving the hematopoietic stem cell transplantation (HSCT) industry forward.
As claimed by, the World Cancer Research Fund 2018 study, one-third of cancer cases (globally) are caused by a lack of physical exercise, obesity, and/or poor nutrition in economically developed nations such as the United States and Europe. Furthermore, 90% of leukemia starts in middle age and worsens with age.
Find your sweet spots for generating winning opportunities in this market.
Which are the Trough Areas faced by the Hematopoietic Stem Cell Transplantation Market?
Adverse Impacts of Hematopoietic Stem Cell Transplantation to Stifle Market Growth
The adverse impacts of hematopoietic stem cell transplantation on organs and body parts such as the gastrointestinal tract, mouth, heart, and lungs associated with the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are expected to slow the market's growth.
Graft-versus-host disease (GVHD) is a consequence of both normal allogeneic and reduced-intensity allogeneic stem cell transplants in which the graft perceives the patient's healthy cells (the host) as foreign and attacks and damages them. A tight HLA match between the donor and the patient reduces but does not eliminate, the risk of GVHD. Graft-versus-host disease has three severity levels: mild, moderate, and severe. In certain situations, it can be fatal.
Region-Wise Insights
How will Hematopoietic Stem Cell Transplantation Market Demand progress in the Asia Pacific?
Increased Frequency of Blood Cancer Diseases for Widening Profit Margins
Asia-Pacific is predicted to expand during the projected timeline of 2023 to 2033 due to the increased frequency of blood cancer diseases and an increase in the number of generic manufacturers in this region.
The expansion of healthcare infrastructure and an aging population will drive the market's growth rate in this area. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7.5% in the assessment period 2023 to 2033.
How attractive are Growth Prospects for Hematopoietic Stem Cell Transplantation in North America?
Rising leukemia incidences to Drive Market Growth in the Region
Over the projected period, North America is likely to lead the entire hematopoietic stem cell transplantation market. Rising leukemia incidences and increased investment in research and development by the public and commercial sectors are the major determinants for the industry in the North American region. For example, according to data provided by the Canadian Cancer Society in May 2022, 6,700 Canadians will be diagnosed with leukemia in 2022. It was also estimated that 4,000 males will be diagnosed with leukemia, and around 2,700 women will be afflicted with leukemia, with 1,300 dying as a result. Stem cell transplants aid in the treatment of leukemia by enabling the body to replenish damaged blood cells with healthy ones.
Hematopoietic stem cells aid in the treatment of leukemia by allowing the body to replace damaged blood cells with healthy blood cells. Stem cells can differentiate into a variety of different types of cells. As a result, rising leukemia incidences are likely to drive demand for hematopoietic stem cell transplantation, fuelling market growth throughout the forecast period.
Prominent factors contributing to the expansion of the hematopoietic stem cell transplantation industry in the future include key product releases, high concentration of market participants or manufacturer's presence, acquisition & alliances among significant players, and expanding the United States. For example, according to the Leukemia and Lymphoma Society's facts and Statistics, around 90,390 persons in the United States were predicted to be diagnosed with lymphoma in 2021. (8,830 Hodgkin Lymphoma cases and 81,560 cases of Non-Hodgkin Lymphoma). As a result, North America is expected to grow at a CAGR of 7.9% in the assessment period 2023 to 2033.
What are the Prominent Factors Shaping the Growth of Hematopoietic Stem Cell Transplantation in Europe?
Overall Increase in Transplant Success Rates fuelling the Market Growth
During the projection period, Europe is expected to lead the worldwide market. The region's supremacy is linked to an overall increase in transplant success rates, simple technical applications, and high population affluence. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.6% in the forecast period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Which is the Most Preferred Transplant Type in the Hematopoietic Stem Cell Transplantation Market?
The Autologous Segment to enhance Sales Prospects
The worldwide hematopoietic stem cell transplantation industry is categorized into two categories: allogeneic and autologous. Despite accounting for a significant portion of the HSCT business in 2021, autologous is an important and sophisticated medical procedure employed in the treatment of a variety of malignant and non-malignant illnesses.
Which is the Most Lucrative Application Segment Type in the Hematopoietic Stem Cell Transplantation Market?
The Bone Marrow Transplant Segment is Predicted to Gain Traction
A bone marrow transplant is a surgery that involves injecting healthy blood-forming stem cells into the body to replace bone marrow that is not producing enough healthy blood cells. A stem cell transplant is another name for a bone marrow transplant. In individuals with malfunctioning or depleted bone marrow, a bone marrow transplant involves the introduction of healthy hematopoietic stem cells. This method is used to treat tumors that damage the bone marrow, such as leukemia, myeloma, lymphoma, and other blood and immune system illnesses.
Increased Research and Development efforts are likely to drive segment growth during the forecast period. For example, Gamida Cell Ltd. stated in October 2020 that the Phase 3 study of omidubicel, an innovative advanced cell therapy under development, is a potentially life-saving therapeutic option for patients in need of bone marrow transplant and fulfilled all three of its secondary goals.
Increased positive initiatives by the public and private sectors toward bone marrow transplants are expected to drive category expansion. For example, the QUINT founders gave around USD 16.0 million in September 2022 to create the QUINT bone marrow transplant center in Dubai. The great effectiveness and benefits of bone marrow transplant in treating acute myeloid leukemia are driving sector expansion.
Start-Ups for Hematopoietic Stem Cell Transplantation Market
Key start-up players in the hematopoietic stem cell transplantation are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key hematopoietic stem cell transplantation start-ups are as follows:
Ankyra, a firm located in the United States, is developing Anchored Immunotherapy, a cytokine suppression-based immunotherapy. It boosts the effectiveness of cytokine immunotherapy and prolongs anti-tumor immunological activation of T-cells, natural killer (NK) cells, and meloids. The company is also working on a platform for administering immune stimulants to localize and maintain cytokines in tumor locations. Unlike systemic dosage, this technique benefits in reducing drug toxicity and improving non-target tissue safety. The company creates medication pipelines for solid tumors in people and animals.
OXvax, located in the United Kingdom, develops a dendritic cell (DC) immuno-oncology vaccination platform. It generates large amounts of CD141+XCR1 DC subset from induced pluripotent stem cells using a unique methodology (iPSC). This novel DC fraction is related to the uncommon myeloid cDC1 DC subset, which has superior tolerance and powerful anti-tumor response. The company's commercially available semi-allogeneic vaccinations cure intractable solid tumor malignancies.
Catamaran Bio is a firm established in the United States that provides TAILWIND, a patented technology package for engineering and manufacturing NK cells. To program NK cells, it uses synthetic biotechnology-enabled tumor microenvironment (TME) switches and the TcBuster transposon system. Furthermore, the suite employs non-viral cell engineering to produce cells with chimeric antigen receptor (CAR) design tailored for NK cells. The company offers CAR-NK cell treatment method development, cell engineering, growth, and cryopreservation for solid tumors.
Market Competition
Key players in the hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio and Talaris Therapeutics.
Recent Developments:
In December 2022, despite missing the primary endpoint, Takeda's Phase 3 AURORA study shows that maribavir has a clinically meaningful and long-lasting effect on Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant patients.
In October 2022, Regen BioPharma, Inc. announced the filing of a provisional patent application with the USPTO titled "Enhancement of T Cell Homing to Tumors through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the US Patent and Trademark Office.
In November 2022, Lonza, a trusted partner in the pharmaceutical, biotech, and nutraceutical industries, introduced an innovative new capsule solution for enteric drug administration. The Capsugel® EnprotectTM capsule does not dissolve in the stomach and releases its contents only in the intestine. By eliminating the need for extra capsule coating or sealing, Capsugel® EnprotectTM capsules greatly simplify the medicinal product production process.
In November 2021, Taiga Biotechnologies, a cell-based immunotherapy company, announced today that the first site in Croatia has completed the site initiation session for the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT)
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 7 Billion
Market Value in 2033
US$ 15 Billion
Growth Rate
CAGR of 8% from 2023 to 2032
Base Year for Estimation
2021
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US Billion and CAGR from 2023 to 2032
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Transplant Type
Indication
Application
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
UK
France
Spain
Italy
China
Japan
South Korea
India
Malaysia
Singapore
Australia
New Zealand
GCC
South Africa
Israel
Key Companies Profiled
Pluristem Therapeutics Inc.
CellGenix GmbH
Regen Biopharma Inc.
Lonza Group
Sanofi
Taiga Biotechnologies, Inc.
Takeda Pharmaceutical Company Limited
Escape Therapeutics, Inc.
Bluebird Bio
Talaris Therapeutics
Customization
Available Upon Request
Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant
Peripheral Blood Stem Cells Transplant
Cord Blood Transplant
Hematopoietic Stem Cell Transplantation Market by Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Frequently Asked Questions
What Role Does the Regulatory Landscape Play in the Market?
Changing rules have an impact on the market by assuring the safety and quality.
How is the Integration of Technology Influencing the Market?
Technological advancements are improving the accuracy and efficiency of transplantation.
What Trends are Shaping the Hematopoietic Stem Cell Transplantation Market?
Personalized therapy and breakthroughs in transplantation techniques.
What are the Key Insights in the Market?
The potential for treating numerous hematological illnesses is seeing increased usage.
What is the Current Market Capitalization of the Industry?
The market capitalization is projected to be around US$ 7 billion.
Table of Content
1. Executive Summary | Hematopoietic Stem Cell Transplantation Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Transplant Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Transplant Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Transplant Type, 2023 to 2033
5.3.1. Allogeneic
5.3.2. Autologous
5.4. Y-o-Y Growth Trend Analysis By Transplant Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Transplant Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
6.3.1. Acute Myeloid Leukemia
6.3.2. Acute Lymphoblastic Leukemia
6.3.3. Hodgkin Lymphoma
6.3.4. Non-Hodgkin Lymphoma
6.3.5. Multiple Myeloma
6.3.6. Other Non-Malignant Disorders
6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
7.3.1. Bone Marrow Transplant
7.3.2. Peripheral Blood Stem Cells Transplant
7.3.3. Cord Blood Transplant
7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Transplant Type
9.2.3. By Indication
9.2.4. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Transplant Type
9.3.3. By Indication
9.3.4. By Application
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Transplant Type
10.2.3. By Indication
10.2.4. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Transplant Type
10.3.3. By Indication
10.3.4. By Application
10.4. Key Takeaways
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Transplant Type
11.2.3. By Indication
11.2.4. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Transplant Type
11.3.3. By Indication
11.3.4. By Application
11.4. Key Takeaways
12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Transplant Type
12.2.3. By Indication
12.2.4. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Transplant Type
12.3.3. By Indication
12.3.4. By Application
12.4. Key Takeaways
13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Transplant Type
13.2.3. By Indication
13.2.4. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Transplant Type
13.3.3. By Indication
13.3.4. By Application
13.4. Key Takeaways
14. Key Countries Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Transplant Type
14.1.2.2. By Indication
14.1.2.3. By Application
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Transplant Type
14.2.2.2. By Indication
14.2.2.3. By Application
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Transplant Type
14.3.2.2. By Indication
14.3.2.3. By Application
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Transplant Type
14.4.2.2. By Indication
14.4.2.3. By Application
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Transplant Type
14.5.2.2. By Indication
14.5.2.3. By Application
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Transplant Type
14.6.2.2. By Indication
14.6.2.3. By Application
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Transplant Type
14.7.2.2. By Indication
14.7.2.3. By Application
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Transplant Type
14.8.2.2. By Indication
14.8.2.3. By Application
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Transplant Type
14.9.2.2. By Indication
14.9.2.3. By Application
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Transplant Type
14.10.2.2. By Indication
14.10.2.3. By Application
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Transplant Type
14.11.2.2. By Indication
14.11.2.3. By Application
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Transplant Type
14.12.2.2. By Indication
14.12.2.3. By Application
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Transplant Type
14.13.2.2. By Indication
14.13.2.3. By Application
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Transplant Type
14.14.2.2. By Indication
14.14.2.3. By Application
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Transplant Type
14.15.2.2. By Indication
14.15.2.3. By Application
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Transplant Type
14.16.2.2. By Indication
14.16.2.3. By Application
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Transplant Type
14.17.2.2. By Indication
14.17.2.3. By Application
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Transplant Type
14.18.2.2. By Indication
14.18.2.3. By Application
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Transplant Type
14.19.2.2. By Indication
14.19.2.3. By Application
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Transplant Type
14.20.2.2. By Indication
14.20.2.3. By Application
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Transplant Type
15.3.3. By Indication
15.3.4. By Application
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pluristem Therapeutics Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. CellGenix GmbH
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Regen Biopharma Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Lonza Group
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Sanofi
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Taiga Biotechnologies, Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Takeda Pharmaceutical Company Limited
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Escape Therapeutics, Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Bluebird Bio
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Talaris Therapeutics
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Transplant Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by Application, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Transplant Type, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by Application, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Transplant Type, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by Application, 2018 to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Value (US$ Million) Forecast by Transplant Type, 2018 to 2033
Table 15: Europe Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by Application, 2018 to 2033
Table 17: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Value (US$ Million) Forecast by Transplant Type, 2018 to 2033
Table 19: Asia Pacific Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 20: Asia Pacific Value (US$ Million) Forecast by Application, 2018 to 2033
Table 21: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MEA Value (US$ Million) Forecast by Transplant Type, 2018 to 2033
Table 23: MEA Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 24: MEA Value (US$ Million) Forecast by Application, 2018 to 2033
List of Charts
Figure 1: Global Value (US$ Million) by Transplant Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Indication, 2023 to 2033
Figure 3: Global Value (US$ Million) by Application, 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Transplant Type, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Transplant Type, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Transplant Type, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 17: Global Attractiveness by Transplant Type, 2023 to 2033
Figure 18: Global Attractiveness by Indication, 2023 to 2033
Figure 19: Global Attractiveness by Application, 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Transplant Type, 2023 to 2033
Figure 22: North America Value (US$ Million) by Indication, 2023 to 2033
Figure 23: North America Value (US$ Million) by Application, 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Transplant Type, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Transplant Type, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Transplant Type, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 37: North America Attractiveness by Transplant Type, 2023 to 2033
Figure 38: North America Attractiveness by Indication, 2023 to 2033
Figure 39: North America Attractiveness by Application, 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Transplant Type, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Indication, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by Application, 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Transplant Type, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Transplant Type, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Transplant Type, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 57: Latin America Attractiveness by Transplant Type, 2023 to 2033
Figure 58: Latin America Attractiveness by Indication, 2023 to 2033
Figure 59: Latin America Attractiveness by Application, 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Europe Value (US$ Million) by Transplant Type, 2023 to 2033
Figure 62: Europe Value (US$ Million) by Indication, 2023 to 2033
Figure 63: Europe Value (US$ Million) by Application, 2023 to 2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Value (US$ Million) Analysis by Transplant Type, 2018 to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Transplant Type, 2023 to 2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Transplant Type, 2023 to 2033
Figure 71: Europe Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 74: Europe Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 76: Europe Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 77: Europe Attractiveness by Transplant Type, 2023 to 2033
Figure 78: Europe Attractiveness by Indication, 2023 to 2033
Figure 79: Europe Attractiveness by Application, 2023 to 2033
Figure 80: Europe Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Value (US$ Million) by Transplant Type, 2023 to 2033
Figure 82: Asia Pacific Value (US$ Million) by Indication, 2023 to 2033
Figure 83: Asia Pacific Value (US$ Million) by Application, 2023 to 2033
Figure 84: Asia Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Value (US$ Million) Analysis by Transplant Type, 2018 to 2033
Figure 89: Asia Pacific Value Share (%) and BPS Analysis by Transplant Type, 2023 to 2033
Figure 90: Asia Pacific Y-o-Y Growth (%) Projections by Transplant Type, 2023 to 2033
Figure 91: Asia Pacific Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 92: Asia Pacific Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 93: Asia Pacific Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 94: Asia Pacific Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 95: Asia Pacific Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 96: Asia Pacific Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 97: Asia Pacific Attractiveness by Transplant Type, 2023 to 2033
Figure 98: Asia Pacific Attractiveness by Indication, 2023 to 2033
Figure 99: Asia Pacific Attractiveness by Application, 2023 to 2033
Figure 100: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 101: MEA Value (US$ Million) by Transplant Type, 2023 to 2033
Figure 102: MEA Value (US$ Million) by Indication, 2023 to 2033
Figure 103: MEA Value (US$ Million) by Application, 2023 to 2033
Figure 104: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 105: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MEA Value (US$ Million) Analysis by Transplant Type, 2018 to 2033
Figure 109: MEA Value Share (%) and BPS Analysis by Transplant Type, 2023 to 2033
Figure 110: MEA Y-o-Y Growth (%) Projections by Transplant Type, 2023 to 2033
Figure 111: MEA Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 112: MEA Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 113: MEA Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 114: MEA Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 115: MEA Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 116: MEA Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 117: MEA Attractiveness by Transplant Type, 2023 to 2033
Figure 118: MEA Attractiveness by Indication, 2023 to 2033
Figure 119: MEA Attractiveness by Application, 2023 to 2033
Figure 120: MEA Attractiveness by Country, 2023 to 2033
